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ABSTRACT 
Background.  Preclinical studies  have shown that several chemotherapeutic agents at low 
doses, may affect the vascular system. Here we report a case of a patient with long term control 
of the disease by metronomic chemotherapy. 
Case presentation. A 62 years old woman underwent left mastectomy in July 2007.  
For the hepatic recovery she performed first-line chemotherapy with doxorubicin plus 
paclitaxel every 21 days. The computer tomography (CT) revaluation after the sixth cycle 
showed a partial response to treatment. It was decided to stop the treatment with doxorubicin 
and paclitaxel, and to start a metronomic therapy with cyclophosphamide 50 mg daily orally 
and Methotrexate 2.5 mg twice daily, two days a week. After six months of this maintenance 
treatment, the CT scan showed a complete response. We evaluated the expression of  vascular 
endothelial growth factor receptor 2 (VEGFR2) on histological sections of the primary tumor 
of our patient, with evidence of overexpression of the receptor. The metronomic treatment is 
still ongoing, and after 60 months the patient maintains a complete response. 
Conclusion. This clinical case also highlights how suitable metronomic chemotherapy can be 
as maintenance therapy, allowing long-term treatment with no relevant toxicity. This case 
suggests that the level of VEGFR2 are predictive of best response to antiangiogenetic therapy. 
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Introduction 
 Most cytotoxic drugs primarily target DNA, either directly or indirectly. This action results 
in death of tumor cells, particularly those that are actively proliferating, often with a directly 
proportional dose-response relationship. 
Preclinical studies  have shown that several chemotherapeutic agents at low doses, devoid of 
any effect on tumor cells, may affect the vascular system, targeting the rapid proliferating 
tumor associated endothelial cells1.Therefore cytotoxic agents, when administered at low doses 
on a frequent or continuous “metronomic” schedule, exert antiangiogenic activity with low 
toxicity2. 
 Low doses of methotrexate (M) have been shown to inhibit endothelial cell proliferation in 
vitro, as well as neovascularization induced by vascular endothelial growth factor in the rabbit 
cornea assay in vivo3. 
 A metronomic administration of cyclophosphamide (C) in mouse models has been shown to 
inhibit the growth of tumors whose cells had developed resistance against the same drug 
administered with the conventional schedule. In this experimental model, the apoptosis of 
vascular endothelial cells preceded that of tumor cells, thus implying an action primarily on 
tumor vasculature 4. 
 Two clinical studies have shown that the metronomic administration of low doses of C and 
M can induce tumor regression in about 20% of patients with advanced breast cancer, with an 
overall clinical benefit (objective responses or stable disease lasting at least 24 weeks) of      
30-40% 5,6. The percentage of complete responses is about 3%. In both studies, the therapy was 
well tolerated. 
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A combined analysis of the two studies has shown a prolonged clinical benefit (≥12 months) in 
15.7% of the patients (95% confidence interval 9.9-21.4%), with median time to progression 
for patients with prolonged clinical benefit of 21 months (range 12-37+ months)7. 
 Here we report a case of a patient with solitary liver metastasis from a triple negative breast 
cancer, with overexpression of the vascular endothelial growth factor receptor 2 (VEGFR2), 
who achieved long term control of the disease by metronomic chemotherapy. 
                                                                            Complete response in patients treated with metronomic chemotherapy 
Case report 
 A 62 years old woman underwent left mastectomy in July 2007. Histological examination 
showed a poorly differentiated infiltrating ductal carcinoma of 6 cm of maximum diameter, 
with metastases in 4 out of 22 axillary nodes. Stage IIIA, pT3  pN2a Mx. Immunohistochemical 
studies showed no expression of estrogen and progestin receptors and a proliferating index 
MIB1 of 60%, HER2 was non-amplified at fluorescent in situ hybridization. 
 The previous medical history was unremarkable, and the patient was taking no medications.  
 A preoperative chest X-ray was normal. After surgery, she completed the staging 
examinations with abdomen ultrasound and bone scan. The ultrasound of the abdomen showed 
a hypoechoic round lesion of the sixth hepatic segment, highly suspicious for metastases. The 
presence of liver metastases was confirmed by a CT scan (Figure 1A) and a PET (Figure 1B). 
The lesion measured 20 mm, and had a standardized uptake value of 5.6. 
 She performed first-line chemotherapy with doxorubicin plus paclitaxel every 21 days, for a 
total of 6 cycles from August 2007 to December 2007. The CT revaluation after the sixth cycle 
showed a partial response to treatment. The lesion measured 6 mm (Figure 1C). 
 In view of the response obtained and the number of cycles performed, it was decided to stop 
the treatment with doxorubicin and paclitaxel, and to start a metronomic therapy with 
cyclophosphamide 50 mg daily orally and Methotrexate 2.5 mg twice daily, two days a week 
(Monday and Tuesday). 
 After six months of this maintenance treatment, the CT scan showed a complete response. 
(Figure 1D). A subsequent PET scan, performed after 21 months from start of maintenance 
therapy, was completely negative. 
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 The metronomic treatment is still ongoing, and after 60 months the patient maintains a 
complete response (Figure 1E), with no side effects. The revaluation occurs periodically with 
either CT or ultrasound of the abdomen and chest X-ray.  
Immunohistochemistry  
 Four-micrometer sections of the tissue samples were mounted on positive-charged slides (BioOptica, 
Milan, Italy), deparaffinised with xylene, rehydrated with EtOH, and the endogenous peroxidase activity 
blocked by 3% hydrogen peroxide solution. Antigens unmasking was performed by citrate buffer at ph  
6 for 30 minutes at 98.5°C. 
The sections were cooled in citrate buffer for 30 minutes, and washed in distilled water. 
The staining was performed by using the automated Dako Autostainer (Dako Corporation, 
Carpinteria, CA, USA).  
 After  the sections were incubated for 1 h at room temp with  primary antibody anti 
VEGFR2 (Imgenex Ab -951) diluted in 1:75 in diluent Dako according the manufacturer 
instructions.  
 The sections were washed with PBS, incubated with universal biotinylated secondary 
antibody, rinsed in PBS, and incubated with streptavidin-peroxidase conjugate (LSAB+kit; 
DAKO) for 15 minutes. Sections were rinsed again in PBS and antibody binding was detected 
by staining with diaminobenzidine/hydrogen peroxidase chromogen solution (DAB+liquid 
substrate–chromogen solution; DAKO Corporation). Finally, sections were rinsed in deionised 
water, counterstained blue by Mayer's Haemalum, and mounted in Eukitt (Bio Optica, Milan, 
Italy).  
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Conclusions 
 Currently, treatment of metastatic breast cancer is essentially palliative, and is chosen 
depending on the hormonal receptor status and the presence or absence of amplification of 
HER2. For triple negative tumors, the therapeutic choices are currently limited to 
chemotherapy and bevacizumab.  
 The value of maintenance therapy, administered to patients who did not experience disease 
progression after a line of systemic treatment, is still debated, although a meta-analysis showed 
that longer first-line chemotherapy duration is associated with marginally longer overall 
survival and a substantially longer progression-free survival8. Maintenance therapy is required 
to be effective in controlling disease progression and to be well tolerated. Metronomic 
chemotherapy has the potential to fulfill these requirements in a number of clinical conditions, 
and is suitable also for patients with triple negative breast cancers, who lack specific targeted 
therapies. 
 The concept of metronomic delivery of chemotherapy has become  relevant for the treatment 
of different types of cancer, among which breast cancer, prostate cancer9, sarcomas10 and 
melanoma11. Its effective use would be fostered by surrogate markers of antiangiogenic activity 
and predictors of response.  
 Measurement of circulating endothelial progenitor cells in peripheral blood is the more 
promising12. Another potential marker is thrombospondin-1 (TSP-1), which is up-regulated by 
low dose metronomic cyclophosphamide13, inhibiting endothelial cell proliferation and 
survival. Clinical studies of metronomic chemotherapy have shown reduction of serum VEGF 
levels, more evident in responders but present also in non-responder 5,6, although its clinical 
relevance and the contribution of platelet-derived VEGF remains unknown.  
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  Molecules related to tumor vascularity, such as VEGFR2, are being studied.   
The VEGF family of angiogenesis stimulators is the main player in breast cancer 
angiogenesis14, and VEGFR2 is the receptor mainly involved in both physiological and 
pathological angiogenesis. Apart from its relevance for drugs directly targeting VEGFR2 itself, 
its expression could have a broader role in predicting the activity of angiogenesis inhibitors.  
 We evaluated the expression of  VEGFR2 on histological sections of the primary tumor of 
our patient, with evidence of overexpression of the receptor (Figure 2). 
Preclinical work has shown highly heterogeneous expression of the receptor in colon cancer 
and melanoma xenografts, but no clear effect on response to metronomic cyclophosphamide in 
these models15, although the authors suggest that response to metronomic therapy could be 
cancer cell specific.   
 Recently a study showed a longer progression free survival in patients with high levels of 
VEGFR2 than those with low levels in patients treated with bevacizumab and chemotherapy. 
This study suggests that the level of VEGFR2 are predictive of best response to 
antiangiogenetic therapy16. 
 The durable complete response to metronomic chemotherapy in our patient highlights the 
importance to assess potential predictors of benefit from this treatment, and suggests further 
study of VEGFR2 at this regard.   
  This clinical case also highlights how suitable metronomic chemotherapy can be as 
maintenance therapy, allowing long-term treatment with no relevant toxicity. 
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Figure legends 
Fig. 1 A) CT and  B) PET scans confirm presence of liver metastasis (20 mm). C) CT             
re-evaluation after the sixth cycle showed a partial response to treatment, with the lesion 
measuring 6 mm. D) CT scan performed after 6 months of maintenance therapy showed a 
complete response. E) CT scan after 60 months of maintenance treatment confirmed the 
continued complete response. 
Fig. 2  VEGFR2 cytoplasmatic immunopositive tumour cells.    
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